A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
マーケット
A pharma giant is moving past one patent cliff — but another is already looming
TradeNews BD、株式・FX・暗号のテープ (2026-10-30): Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks. 一次ソース: CNBC Top News の原文 (cnbc.com).